Stay updated on Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial
Sign up to get notified when there's something new on the Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial page.

Latest updates to the Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial page
- ChecktodayChange DetectedAn NIH announcement banner describes a transition from the term “Artificial Intelligence” to “Super Intelligence” across NIH content. The study record itself remains inaccessible behind a 403 error.SummaryDifference1%

- Check7 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoChange DetectedThe ClinicalTrials.gov error page displays an updated site revision number, from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check35 days agoChange DetectedThe study record page now displays a 403 Forbidden error, indicating access to the content is blocked. The visible portion shows the site chrome (header/footer) while the actual study details are not accessible.SummaryDifference17%

- Check56 days agoChange Detected- Revision: v3.6.6 is now shown on the page, replacing Revision: v3.6.5. This indicates a small update to the page's template or content rendering without changing the study information.SummaryDifference0.1%

- Check77 days agoChange DetectedA new footer line 'Revision: v3.6.5' has been added. The text items 'clinical study report synopsis', 'AbbVie', 'Helpful Links Provided by', and the previous 'Revision: v3.6.4' have been removed.SummaryDifference0.2%

Stay in the know with updates to Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Placebo in Psoriasis in Russia Clinical Trial page.